Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267554 | 0.91 | CYP1A2 (0.41) | CYP1A2TDP1PHGDHMGLL | |
| SCHEMBL30920949 | 0.87 | — | — | |
| SCHEMBL2590891 | 0.82 | CYP1A2 (0.40) | CYP1A2KMT2A | |
| SCHEMBL24702161 | 0.81 | POLB (0.36) | CHKAPOLBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL29120571 | 0.78 | CYP1A2 (0.38) | CYP1A2KMT2A | |
| SCHEMBL1106430 | 0.75 | KDM4E (0.33) | CHKAHTTTDP1KMT2ALMNA | |
| SCHEMBL23277743 | 0.75 | CYP1A2 (0.42) | CYP1A2 | |
| SCHEMBL14725163 | 0.75 | SIGMAR1 (0.41) | CYP1A2SIGMAR1 | |
| SCHEMBL22327631 | 0.72 | KDM4E (0.30) | TDP1 | |
| SCHEMBL20419439 | 0.71 | KDM4E (0.31) | HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-2748166-B1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF | ASANA BIOSCIENCES LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017095898-A1 | USES OF PYRIMIDO-PYRIMIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2016-09-08 | — | — | US | disclosed |
| US-9382277-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | CYP1A2 258/4885CHKA 2816/4885HTT 4581/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | CYP1A2 1702/4885CHKA 1148/4885HTT 4805/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | CYP1A2 258/4885CHKA 2816/4885HTT 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.